Drug Delivery · 2012 · 156 citations · 29 references
PharmacyPharmaceuticsPharmacologyCancer PharmacologyDrug DeliveryPharmaceutical FormulationCancer Drug DeliveryLipid-based Drug Delivery SystemsLipid-based Oral FormulationsNanocarriers For TherapeuticsTopical PreparationsEx Vivo Skin PermeationLipid-based Drug CarriersLiposomesLocal Drug DeliveryMembrane Composition EffectsNanocarrier Encapsulation EfficiencyTopical Formulation DesignVesicle Membranes
Topical administration of celecoxib proved to be an effective mean of preventing skin cancer development and improving anticancer drugs effectiveness in skin tumors treatment. The aim of this study was the development of an effective topical formulation of celecoxib, able to promote drug skin delivery, providing its in depth penetration through the skin layers. Three kinds of vesicular formulations have been investigated as drug carriers: liposomes containing a surfactant, or transfersomes and ethosomes, containing suitable edge activators. Firstly, the effect of membrane composition variations on the system performance has been evaluated for each vesicle type. Selected formulations were characterized for particle size, polydispersity index and encapsulation efficiency. The best formulations were subjected to ex vivo permeation studies through excised human skin. All vesicular formulations markedly (p < 0.001) improved the drug amount penetrated into the skin with respect to an aqueous suspension, from 2.0 to 6.5, up to 9.0 folds for liposomes, transfersomes and ethosomes, respectively. In particular, ethosomes containing Tween 20 as edge activator not only showed the best vesicle dimensions and homogeneity, and the highest encapsulation efficacy (54.4%), but also enabled the highest increase in drug penetration through the skin, probably due to the simultaneous presence in their composition of ethanol and Tween 20, both acting as permeation enhancers. Therefore, among the various vesicular formulations examined in the study, Tween 20-ethosomes can be considered the most promising one as carrier for topical celecoxib applications aimed to prevent skin cancer development and increase the anticancer drugs effectiveness against skin tumors.
29
Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
Howard W. Rogers, Martin A. Weinstock, Ashlynne R. Harris et al. · Archives of Dermatology · 2010 · 1.2K citations · Full text
Medicine, Dermatology, Oncology +15
Prevalence of a History of Skin Cancer in 2007
Robert S. Stern · Archives of Dermatology · 2010 · 423 citations
Medicine, Dermatology, Oncology +16
Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes
Nava Dayan, Elka Touítou · Biomaterials · 2000 · 421 citations
Pharmacy, Dermatology, Pharmaceutics +14